A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite

Overview

Journal J Huntingtons Dis

Publisher Sage Publications

Date 2019 Jul 1

PMID 31256146

Citations 4

Authors

Ellen van der Plas

Robin Schubert

Ralf Reilmann

Peggy C Nopoulos

Affiliations

Soon will be listed here.

Abstract

Q-Motor is utilized across various clinical trials in adults with Huntington's disease (HD) to provide quantitative, reliable assessments of motor abilities. With gene-knockdown therapies entering the clinic, development of preventative therapies for pediatric carriers of the HD mutation seems imminent. It is currently unclear if Q-Motor is useful for tracking changes in motor abilities in pediatric HD patients or at-risk youth, as most assessments have never been administered in children. We demonstrate the feasibility of administering Q-Motor tasks in a sample of children recruited from the community, and we show that Q-Motor is sensitive to age-related changes in motor abilities.

Citing Articles

Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.

Aqel S, Ahmad J, Saleh I, Fathima A, Al Thani A, Mohamed W Biology (Basel). 2025; 14(2).

PMID: 40001897 PMC: 11852324. DOI: 10.3390/biology14020129.

Mutant Huntingtin Drives Development of an Advantageous Brain Early in Life: Evidence in Support of Antagonistic Pleiotropy.

Neema M, Schultz J, Langbehn D, Conrad A, Epping E, Magnotta V Ann Neurol. 2024; 96(5):1006-1019.

PMID: 39115048 PMC: 11496017. DOI: 10.1002/ana.27046.

A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders.

Marshall R, Menniti F, Tepper M Cells. 2024; 13(14.

PMID: 39056811 PMC: 11274801. DOI: 10.3390/cells13141230.

LASSI-L detects early cognitive changes in pre-motor manifest Huntington's disease: a replication and validation study.

Sierra L, Hughes S, Ullman C, Hall A, Pandeya S, Schubert R Front Neurol. 2023; 14:1191718.

PMID: 37533473 PMC: 10393264. DOI: 10.3389/fneur.2023.1191718.

Effects of age and sex on outcomes of the Q-Motor speeded finger tapping and grasping and lifting tests-findings from the population-based BiDirect Study.

Teismann H, Schubert R, Reilmann R, Berger K Front Neurol. 2022; 13:965031.

PMID: 36247774 PMC: 9561931. DOI: 10.3389/fneur.2022.965031.

References

Winder J, Roos R, Burgunder J, Marinus J, Reilmann R . Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification. Mov Disord Clin Pract. 2018; 5(3):290-295. PMC: 6174470. DOI: 10.1002/mdc3.12618. View

Sampaio C, Borowsky B, Reilmann R . Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. Mov Disord. 2014; 29(11):1419-28. DOI: 10.1002/mds.26021. View

Lin Q, Luo J, Wu Z, Shen F, Sun Z . Characterization of fine motor development: dynamic analysis of children's drawing movements. Hum Mov Sci. 2015; 40:163-75. DOI: 10.1016/j.humov.2014.12.010. View

Wild E . Huntington's Disease: The Most Curable Incurable Brain Disorder?. EBioMedicine. 2016; 8:3-4. PMC: 4919568. DOI: 10.1016/j.ebiom.2016.05.023. View

Tabrizi S, Scahill R, Owen G, Durr A, Leavitt B, Roos R . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013; 12(7):637-49. DOI: 10.1016/S1474-4422(13)70088-7. View

Turesky T, Olulade O, Luetje M, Eden G . An fMRI study of finger tapping in children and adults. Hum Brain Mapp. 2018; 39(8):3203-3215. PMC: 6052794. DOI: 10.1002/hbm.24070. View

. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2):136-42. DOI: 10.1002/mds.870110204. View

Kieburtz K, Reilmann R, Olanow C . Huntington's disease: Current and future therapeutic prospects. Mov Disord. 2018; 33(7):1033-1041. DOI: 10.1002/mds.27363. View

Bechtel N, Scahill R, Rosas H, Acharya T, van den Bogaard S, Jauffret C . Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010; 75(24):2150-60. PMC: 3013584. DOI: 10.1212/WNL.0b013e3182020123. View

10.

Tabrizi S, Langbehn D, Leavitt B, Roos R, Durr A, Craufurd D . Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009; 8(9):791-801. PMC: 3725974. DOI: 10.1016/S1474-4422(09)70170-X. View

11.

Lee J, Mathews K, Schlaggar B, Perlmutter J, Paulsen J, Epping E . Measures of growth in children at risk for Huntington disease. Neurology. 2012; 79(7):668-74. PMC: 3414667. DOI: 10.1212/WNL.0b013e3182648b65. View

12.

Muller K, Homberg V . Development of speed of repetitive movements in children is determined by structural changes in corticospinal efferents. Neurosci Lett. 1992; 144(1-2):57-60. DOI: 10.1016/0304-3940(92)90715-j. View

13.

Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon A . Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology. 2001; 57(5):920-4. DOI: 10.1212/wnl.57.5.920. View

14.

Garvey M, Ziemann U, Bartko J, Denckla M, Barker C, Wassermann E . Cortical correlates of neuromotor development in healthy children. Clin Neurophysiol. 2003; 114(9):1662-70. DOI: 10.1016/s1388-2457(03)00130-5. View

15.

Reilmann R, Rouzade-Dominguez M, Saft C, Sussmuth S, Priller J, Rosser A . A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord. 2015; 30(3):427-31. DOI: 10.1002/mds.26174. View

16.

Reilmann R, Schubert R . Motor outcome measures in Huntington disease clinical trials. Handb Clin Neurol. 2017; 144:209-225. DOI: 10.1016/B978-0-12-801893-4.00018-3. View

17.

Giedd J, Blumenthal J, Jeffries N, Castellanos F, Liu H, Zijdenbos A . Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999; 2(10):861-3. DOI: 10.1038/13158. View

18.

Tabrizi S, Reilmann R, Roos R, Durr A, Leavitt B, Owen G . Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2011; 11(1):42-53. DOI: 10.1016/S1474-4422(11)70263-0. View

19.

Fietzek U, Heinen F, Berweck S, Maute S, Hufschmidt A, Schulte-Monting J . Development of the corticospinal system and hand motor function: central conduction times and motor performance tests. Dev Med Child Neurol. 2000; 42(4):220-7. DOI: 10.1017/s0012162200000384. View

20.

Reilmann R, McGarry A, Grachev I, Savola J, Borowsky B, Eyal E . Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2018; 18(2):165-176. DOI: 10.1016/S1474-4422(18)30391-0. View